Drug Trial Radar · NCT01720446
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jun 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,297
Actual
Start
Feb 21, 2013
Primary completion
Mar 15, 2016
Study completion Mar 15, 2016
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
semaglutideDrug
Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
semaglutideDrug
Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
placeboDrug
Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal StrokeTime frame: Time from randomisation up to end of follow-up (scheduled at week 109)
Locations
253 sites in 21 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Chandler, Arizona
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Greenbrae, California
Novo Nordisk Investigational Site
Lancaster, California
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Mission Hills, California
Novo Nordisk Investigational Site
Monterey, California
Novo Nordisk Investigational Site
Northridge, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Ramon, California
Novo Nordisk Investigational Site
Ventura, California
Novo Nordisk Investigational Site
Aurora, Colorado
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Bradenton, Florida
Novo Nordisk Investigational Site
Crystal River, Florida
Novo Nordisk Investigational Site
DeLand, Florida
Novo Nordisk Investigational Site
Jacksonville, Florida
Novo Nordisk Investigational Site
Melbourne, Florida
Novo Nordisk Investigational Site
Melbourne, Florida
Novo Nordisk Investigational Site
Ocala, Florida
Novo Nordisk Investigational Site
Ponte Vedra, Florida
Novo Nordisk Investigational Site
Spring Hill, Florida
Novo Nordisk Investigational Site
St. Petersburg, Florida
Novo Nordisk Investigational Site
Dunwoody, Georgia
Novo Nordisk Investigational Site
Lawrenceville, Georgia
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Crystal Lake, Illinois
Novo Nordisk Investigational Site
Gurnee, Illinois
Novo Nordisk Investigational Site
Michigan City, Indiana
Novo Nordisk Investigational Site
Mishawaka, Indiana
Novo Nordisk Investigational Site
Wichita, Kansas
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Monroe, Louisiana
Novo Nordisk Investigational Site
New Orleans, Louisiana
Novo Nordisk Investigational Site
Methuen, Massachusetts
Novo Nordisk Investigational Site
North Dartmouth, Massachusetts
Novo Nordisk Investigational Site
Kalamazoo, Michigan
Showing 40 of 253 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.